Trigone Pharma
Trigone Pharma is an early-stage Israeli biotech developing intravesical sustained-release drug therapies for patients with bladder diseases and urological cancers.
- Company typePrivate
- Founded2020
- HeadquartersRa'anana, Israel
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Trigone Pharma does
Trigone Pharma is a privately held, for-profit biotechnology company founded in 2020 and headquartered in Ra'anana, Israel. According to the firmographic record, the company develops intravesical sustained-release therapies intended for bladder diseases and urological cancers. This positioning indicates a localized, prolonged-exposure drug-delivery platform rather than a systemic-therapy approach, targeting organ-confined urological indications. The current headcount of 1–10 employees is consistent with an early, preclinical-to-early-clinical stage of development.
The company's underlying technology, pipeline, and business model cannot be characterized in detail from the available data. No products, pricing models, distribution channels, customer segments, partnerships, awards, patents, or trademarks are disclosed. The company website (https://www.trigonepharma.com) currently serves only a verification/loading page with no substantive content. There is no documented management team, no funding history, no M&A or strategic transaction activity, and no regulatory milestones in the supplied record, leaving commercialization mechanics, capital structure, and pipeline depth unsubstantiated by the available evidence.
Trigone Pharma firmographics
Firmographics- Name
- Trigone Pharma
- Website
- https://trigonepharma.com
- Company type
- Private
- Founded year
- 2020
- Headcount range
- 1–10 employees
- Short description
- Trigone Pharma is an early-stage Israeli biotech developing intravesical sustained-release drug therapies for patients with bladder diseases and urological cancers.
- Ownership category
- akta.pro rank
Trigone Pharma industry classification
Industry- Product category
- Urological Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
- akta.pro secondary industry
- Nephrology & Urology Pharmaceuticals (HLAIAAAM)
Keywords
Where Trigone Pharma is headquartered
LocationHeadquarters
- HQ city
- Ra'anana
- HQ country
- Israel
- HQ region
- Middle East
Markets served
Trigone Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Trigone Pharma product offering
Product offeringCore offering
Trigone Pharma develops intravesical sustained-release therapies for bladder diseases and urological cancers. The company focuses on drug delivery approaches that administer therapeutics directly into the bladder and release them over extended periods to treat urological conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- Intravesical sustained-release therapies
Companies that use Trigone Pharma
Customer profileIdeal customer profiles1 record
Trigone Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Trigone Pharma partnerships and signals
Strategic signalRecent moves1 record
Expansion highlights2 records
Trigone Pharma competitors and assessment
Company assessmentBroad incumbents
- AbbVie: AbbVie acquired TARIS Biomedical and is a major oncology/urology incumbent. Its ownership of TARIS's intravesical sustained-release platform makes it both a direct technology owner and a likely strategic acquirer of complementary assets like Trigone.
- Ferring Pharmaceuticals: Ferring is a specialty pharma with deep urology/uro-oncology presence, including bladder cancer therapies. Its focus on urological specialty products makes it a natural strategic acquirer for a sustained-release intravesical developer like Trigone.
- Bristol-Myers Squibb: BMS markets Opdivo for urothelial carcinoma and is a major oncology incumbent. Its established bladder cancer franchise and immuno-oncology pipeline make it a relevant comparator and potential strategic acquirer in the space.
- Merck & Co. Merck's Keytruda is approved for NMIBC and other urothelial cancers, making it the dominant large-cap incumbent in bladder cancer immunotherapy and a likely strategic comparator for any novel intravesical therapy.
- Astellas Pharma: Astellas markets Padcev and has a significant oncology/urology franchise including bladder cancer products. As a large incumbent in urological oncology, it represents both a potential acquirer and competitor for Trigone's targeted indications.
Emerging players
- enGene: enGene is developing intravesical gene therapies (EG-70) for non-muscle invasive bladder cancer. While its modality is gene therapy rather than small-molecule sustained release, it competes in the same intravesical NMIBC treatment paradigm.
- Photocure ASA: Photocure specializes in bladder cancer diagnostics (Hexvix/Cysview) used during TURBT procedures. While focused on detection rather than sustained-release treatment, it is a focused urology-oncology company serving the same bladder cancer care pathway.
- Lipomedix Pharmaceuticals: Lipomedix developed intravesical therapies for NMIBC, including a thermosensitive liposomal formulation. As a small specialty developer of intravesical bladder cancer therapies, it is a closely comparable emerging peer to Trigone.
Direct peers
- UroGen Pharma: UroGen Pharma develops intravesical therapies for urological cancers, most notably Jelmyto (mitomycin) for low-grade upper tract urothelial cancer. It is the most direct public comparable to Trigone's intravesical sustained-release focus on bladder and urological cancers.
- TARIS Biomedical: TARIS Biomedical developed intravesical sustained-release drug-device systems for bladder cancer and was acquired by AbbVie. Its lead program TAR-200 (gemcitabine) directly parallels Trigone's sustained-release intravesical approach for urological cancers.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Trigone Pharma social profiles
Digital presenceTrigone Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trigone Pharma leadership team
Management profileNumber of profiles
Trigone Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trigone Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trigone Pharma
What does Trigone Pharma do?
Trigone Pharma develops intravesical sustained-release therapies for bladder diseases and urological cancers. The company focuses on drug delivery approaches that administer therapeutics directly into the bladder and release them over extended periods to treat urological conditions.
When was Trigone Pharma founded?
Trigone Pharma was founded in 2020. It employs 1 to 10 people.
Where is Trigone Pharma based?
Trigone Pharma is headquartered in Ra'anana, Israel, in the Middle East region.
Who are Trigone Pharma's main competitors?
Broad incumbents on record are AbbVie, Ferring Pharmaceuticals, Bristol-Myers Squibb, Merck & Co. and Astellas Pharma. Emerging players are enGene, Photocure ASA and Lipomedix Pharmaceuticals. Direct peers are UroGen Pharma and TARIS Biomedical.
Does Trigone Pharma have an API?
No public API is recorded for Trigone Pharma.
What industry is Trigone Pharma in?
Trigone Pharma's product category is Urological Therapeutics. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIAAAM, Nephrology & Urology Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.